1. Search Result
Search Result
Results for "

Antiplatelet

" in MedChemExpress (MCE) Product Catalog:

146

Inhibitors & Agonists

3

Biochemical Assay Reagents

4

Peptides

2

Inhibitory Antibodies

48

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15876

    Drug Metabolite P2Y Receptor Cardiovascular Disease
    Clopidogrel thiolactone is an important intermediate in the metabolism of clopidogrel (HY-15283). Clopidogrel thiolactone has antiplatelet aggregatione effects. Clopidogrel is a P2Y12 receptor inhibitor that exerts antiplatelet effects .
    Clopidogrel thiolactone
  • HY-N2299

    Others Cardiovascular Disease
    Morusinol is a flavonoid isolated from Morus alba root bark. Morusinol has an antiplatelet activity and  significantly inhibits arterial thrombosis in vivo .
    Morusinol
  • HY-N2909

    Others Inflammation/Immunology
    Aurantiamide is an orally active constituent of Portulaca oleracea L and has various biological activities, including antioxidant, antiplatelet, anti-inflammatory, and antitumor activities .
    Aurantiamide
  • HY-146498

    P2Y Receptor Cardiovascular Disease Cancer
    Antiplatelet agent 1 (compound 7q) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 1 can be used for researching platelet aggregation .
    Antiplatelet agent 1
  • HY-146499

    P2Y Receptor Cardiovascular Disease Cancer
    Antiplatelet agent 2 (compound 7p) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 2 can be used for researching platelet aggregation .
    Antiplatelet agent 2
  • HY-111755

    P2Y Receptor Cardiovascular Disease
    Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .
    Oral antiplatelet agent 1
  • HY-N7991

    Others Cardiovascular Disease
    Rubiayannone A is an anthraquinone glycoside with an antiplatelet aggregation activity .
    Rubiayannone A
  • HY-N1861

    Quercetin 3-O-methyl ether peracetate

    P2Y Receptor Cardiovascular Disease Cancer
    3-O-Methylquercetin tetraacetate is an antiplatelet agent. 3-O-Methylquercetin tetraacetate has potent antiplatelet effect on arachidonic acid, collagen-induced and PAF-induced platelet aggregation .
    3-O-Methylquercetin tetraacetate
  • HY-N3048

    Others Cardiovascular Disease
    Piperlotine D is an antiplatelet aggregation agent. Piperlotine D can be extracted from Piper lolot with antiplatelet aggregation activity. Piperlotine D inhibits arachidonic acid-induced platelet aggregation with an IC50 of 43.4 μg/mL .
    Piperlotine D
  • HY-162374

    Calcium Channel Cardiovascular Disease
    ANO61 is a dibenzyl formamide derivative, which exhibits an antiplatelet efficacy through modulation of thrombin-induced Ca 2+ response with an IC50 of 47.7 μM .
    ANO61
  • HY-118072

    Others Neurological Disease
    Aspalatone is an orally active antiplatelet aggregant with IC50 of 180 μM. Aspalatone has antioxidant and neuroprotective activities .
    Aspalatone
  • HY-110118

    PPAR Metabolic Disease
    Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC50s of 35.6 nM and 1053 nM for PPARα and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity .
    Edaglitazone
  • HY-125123

    Others Cardiovascular Disease
    Euchrestaflavanone A is a flavonoid found in the root bark of Cudrania tricuspidate. Euchrestaflavanone A inhibits platelet aggregation and has some antiplatelet and antithrombotic properties, making it a potential compound for thromboprophylaxis .
    Euchrestaflavanone A
  • HY-119410

    HN11500

    Prostaglandin Receptor Cardiovascular Disease
    Linotroban (HN11500), a Sulotroban (HY-158332) derivative, is an orally active, potent non-prostanoid thromboxane receptor antagonist (TXRA) with a strong antiplatelet profile. Linotroban is used as antithrombotic agent .
    Linotroban
  • HY-15799

    P2Y Receptor Cardiovascular Disease
    AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders .
    AZD1283
  • HY-B1735

    Prostaglandin Receptor Cardiovascular Disease
    Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .
    Picotamide
  • HY-B0366A
    Cyproheptadine hydrochloride
    3 Publications Verification

    5-HT Receptor Cardiovascular Disease Neurological Disease Cancer
    Cyproheptadine hydrochloride is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders .
    Cyproheptadine hydrochloride
  • HY-B1622
    Cyproheptadine
    3 Publications Verification

    5-HT Receptor Apoptosis Cardiovascular Disease Neurological Disease Cancer
    Cyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders .
    Cyproheptadine
  • HY-N4228

    Platelet-activating Factor Receptor (PAFR) Cancer
    6-Methoxydihydroavicine is an alkaloid isolated from Zanthoxylum integrifoliolum. 6-Methoxydihydroavicine has antiplatelet activities and inhibits AA-, collagen- and PAF-induced platelet aggregation in vitro .
    6-Methoxydihydroavicine
  • HY-N2081
    Skimmianine
    2 Publications Verification

    Others Inflammation/Immunology Cancer
    Skimmianine is a furoquinoline alkaloid present mainly in the Rutaceae family, with antispastic, anti-inflammatory activities and antiplatelet aggregation effect. Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity .
    Skimmianine
  • HY-N6020A

    Others Others
    (+)-Butin is the R enantiomer of Butin. Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera, with strong antioxidant, antiplatelet and anti-inflammatory activities .
    (+)-Butin
  • HY-B0312
    Dipyridamole
    4 Publications Verification

    Phosphodiesterase (PDE) Apoptosis Cardiovascular Disease Cancer
    Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis .
    Dipyridamole
  • HY-B0428A
    Ozagrel sodium
    1 Publications Verification

    OKY-046 sodium

    Prostaglandin Receptor Cardiovascular Disease
    Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
    Ozagrel sodium
  • HY-B0428B
    Ozagrel hydrochloride
    1 Publications Verification

    OKY-046 hydrochloride

    Prostaglandin Receptor Cardiovascular Disease
    Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM .
    Ozagrel hydrochloride
  • HY-162408

    Protease Activated Receptor (PAR) Others
    PAR4 antagonist 3 (Compound 36) is a selective antagonist for protease activated receptor 4 (PAR4). PAR4 antagonist 3 exhibits antiplatelet efficacy with IC50 of 26.1 nM. PAR4 antagonist 3 improves metabolic stablility in human liver microsomes with T1/2 of 97.6 min .
    PAR4 antagonist 3
  • HY-162409

    Protease Activated Receptor (PAR) Others
    PAR4 antagonist 4 (Compound 37) is a selective antagonist for protease activated receptor 4 (PAR4). PAR4 antagonist 3 exhibits antiplatelet efficacy with IC50 of 14.2 nM. PAR4 antagonist 3 improves metabolic stablility in human liver microsomes with T1/2 of 42.5 min .
    PAR4 antagonist 4
  • HY-B0428
    Ozagrel
    1 Publications Verification

    OKY-046

    Prostaglandin Receptor Cardiovascular Disease
    Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
    Ozagrel
  • HY-106066

    UK38485

    Others Cardiovascular Disease
    Dazmegrel (UK-38485) is a thromboxane synthetase inhibitor which inhibits Thromboxane A2 (TXA2) synthesis and exhibits antiplatelet vasodilator effects. Dazmegrel can be utilized in thrombosis research .
    Dazmegrel
  • HY-A0221

    R 68070

    Prostaglandin Receptor Inflammation/Immunology
    Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .
    Ridogrel
  • HY-B1622R

    5-HT Receptor Apoptosis Cardiovascular Disease Neurological Disease
    Cyproheptadine (Standard) is the analytical standard of Cyproheptadine. This product is intended for research and analytical applications. Cyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders .
    Cyproheptadine (Standard)
  • HY-B0366AR

    5-HT Receptor Cardiovascular Disease Neurological Disease Cancer
    Cyproheptadine (hydrochloride) (Standard) is the analytical standard of Cyproheptadine (hydrochloride). This product is intended for research and analytical applications. Cyproheptadine hydrochloride is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders .
    Cyproheptadine hydrochloride (Standard)
  • HY-107867

    Others Cardiovascular Disease
    Clopidogrel sulfate is an antiplatelet agent. Specifically, Clopidogrel sulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel sulfate can be used for research of heart disease and stroke .
    (±)-Clopidogrel bisulfate
  • HY-N2081R

    Others Inflammation/Immunology Cancer
    Skimmianine (Standard) is the analytical standard of Skimmianine. This product is intended for research and analytical applications. Skimmianine is a furoquinoline alkaloid present mainly in the Rutaceae family, with antispastic, anti-inflammatory activities and antiplatelet aggregation effect. Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity .
    Skimmianine (Standard)
  • HY-B0312R

    Phosphodiesterase (PDE) Apoptosis Cardiovascular Disease Cancer
    Dipyridamole (Standard) is the analytical standard of Dipyridamole. This product is intended for research and analytical applications. Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis .
    Dipyridamole (Standard)
  • HY-B0428BR

    Prostaglandin Receptor Cardiovascular Disease
    Ozagrel (hydrochloride) (Standard) is the analytical standard of Ozagrel (hydrochloride). This product is intended for research and analytical applications. Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM .
    Ozagrel hydrochloride (Standard)
  • HY-N1631

    1-Hydroxyrutaecarpine

    Others Others
    1-Hydroxyrutaecarpine (compound 1a) is a hydroxy-derivative of rutaecarpine. 1-Hydroxyrutaecarpine shows cytotoxicities with ED50s of 3.72, 7.44 µg/mL for P-388 and HT-29 cells, respectively. 1-Hydroxyrutaecarpine shows antiplatelet activity .
    1-Hydroxyrutecarpine
  • HY-N11920

    Platelet-activating Factor Receptor (PAFR) Infection Neurological Disease Inflammation/Immunology
    Kadsurenin B is a PAF (platelet-activating factor) antagonist with neuroprotective activity. Kadsurenin B has a wide range of pharmacological research potential, such as antibacterial, anti-inflammatory, neuroprotective, antioxidant, antiplatelet aggregation, cytotoxic, antiparasitic, etc .
    Kadsurenin B
  • HY-N9488

    Girinimbin

    Apoptosis Bacterial Parasite Infection Inflammation/Immunology Cancer
    Girinimbine (Girinimbin) is a carbazole alkaloid with a variety of biological effects. Girinimbine can induce apoptosis, and has antitrypanosomal, antiplatelet activity, antibacterial activity, anti-inflammatory, antioxidant and antitumor activities .
    Girinimbine
  • HY-19638A
    Cangrelor tetrasodium
    1 Publications Verification

    AR-C69931MX tetrasodium

    P2Y Receptor Cardiovascular Disease Inflammation/Immunology
    Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .
    Cangrelor tetrasodium
  • HY-P99560

    C4G1; YM-337

    Integrin Cardiovascular Disease
    Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
    Tadocizumab
  • HY-106080A

    U-63557A

    Others Cardiovascular Disease
    Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
    Furegrelate sodium
  • HY-106080

    U-63557A free acid

    Others Cardiovascular Disease
    Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate is being developed as an antiplatelet agent .
    Furegrelate
  • HY-118284
    Vicagrel
    1 Publications Verification

    P2Y Receptor Cardiovascular Disease
    Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .
    Vicagrel
  • HY-105218

    BMS-180291

    Prostaglandin Receptor Cardiovascular Disease Endocrinology Cancer
    Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
    Ifetroban
  • HY-105218A
    Ifetroban sodium
    1 Publications Verification

    BMS-180291 sodium

    Prostaglandin Receptor Cardiovascular Disease Endocrinology Cancer
    Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
    Ifetroban sodium
  • HY-115911

    Glycoprotein VI Cardiovascular Disease
    GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent .
    GPVI antagonist 2
  • HY-115912

    Glycoprotein VI Cardiovascular Disease
    GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent .
    GPVI antagonist 3
  • HY-17459
    Clopidogrel hydrogen sulfate
    Maximum Cited Publications
    21 Publications Verification

    (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate

    Cytochrome P450 P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation .Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
    Clopidogrel hydrogen sulfate
  • HY-W062836

    Guanylate Cyclase Cardiovascular Disease
    BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research .
    BAY 41-8543
  • HY-107146

    P1pal-7

    Protease Activated Receptor (PAR) Cardiovascular Disease Cancer
    PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible protease-activated receptor-1 (PAR1) antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins. PZ-128 has antiplatelet, anti-metastatic, anti-angiogenic and anticancer effects .
    PZ-128

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: